Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse

NCT00208169 is registered in ClinicalTrials.gov with Creighton University as lead sponsor.

NCT NCT00208169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00208169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse
Lead sponsor
Creighton University
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2005
Completion date
June 30, 2007
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety disorders, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophrenia, substance abuse